Glycemic and Insulinemic Index Determination of Two Products: Fructilight® and A Fruit Fructo-Oligosaccharides in Sweet Matrix

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine glycemic and insulinemic index of 2 sweet syrups : FructiLight® and fruit Fructo-oligosaccharides in sweet matrix compared to glucose.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

12 male and female healthy adults are included in the study. During 5 separated visits subjects consume either 50 g of glucose in water (3 glucose response tests) or portion of syrup supply the equivalent of 50 g of glycaemic carbohydrates (2 syrup response tests).

Experimental sessions last 3 hours with 9 veinous and capillary blood taking. The experimental meals are served at t0 and are consumed between 12 and 15 minutes maximum. At time -5, 0, 15, 30, 45, 60, 90, 120 and 180 minutes, glucose is measured out on capillary blood and insulin is measured out on venous blood.

The glycemic index and Insulinemic index determination of the 2 syrups start by the calculation for each glycemia and insulinemia responses of the AUC over 120 min. The AUC(0-120min) is computed following the FAO recommendation (cf. FAO/WHO 1998), i.e. using the trapezoidal incremental method and not taking into account the area beneath the fasting concentration. then GI and II values expressed in percentage are calculated by dividing the AUC(0-120min) for test syrup products by the AUC(0-120min) for the glucose reference and multiplying by 100.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Glycemic index Insulinemic index Fructo-oligosaccharide syrup Fructose syrup Aged between eighteen and fifty years old BMI between nineteen and twenty five kg/m² Non diabetic or pre-diabetic Without liver, renal or gastro-intestinal disorder Non-smoker

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup

One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18 to 50 years (limits included
* With a BMI between 19 and 25 kg/m² (limits included)
* Non-smoker
* Non-menopausal female with reliable contraception for two cycles before the beginning of the study and agreeing to keep it during the entire duration of the study
* Capable and willing to conform to the protocol and accepting to give his written informed consent
* Registered to Social Security System
* Accepting to be registered on the Volunteers in biomedical research file

After biological analysis, the subjects will be included on the following criteria :

* Fasting blood sugar level \< 1,1 g/L
* Blood sugar level 120 minutes after 75g glucose intake \< 1.4 g/L
* Complete blood count without significant clinically abnormality according to the investigator
* ASAT \< 1,55 µkat/L
* ALAT \< 1,7 µkat/L
* GGT \< 2,55 µkat/L
* 45 \< Creatinine \< 104 µmol/L
* 1.7 \< Urea \< 8.3 mmol/L

Exclusion Criteria

* Known food allergy, in particular to one of the tested products' components or to related products
* Personal history of hypercholesterolemia, high blood pressure, diabetes or glucose intolerance
* Renal insufficiency
* Liver disorders ongoing
* Gastrointestinal disorders, clinically significant according the investigator
* Use of medications which could affect lipidic or carbohydrate metabolism
* Disease or medication with impact on nutrients digestion and absorption
* Pregnant or breastfeeding women
* General anaesthetic in the month before the study
* Presenting a psychological or linguistic incapability to sign the informed consent
* Refusing to sign the informed consent
* Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision
* Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros
* Impossible to contact in case of emergency
* Major or medical or surgical event with hospitalization in the last 3 months
* Taking part in an-other clinical trial or being in the exclusion period of a previous clinical trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CRITT Bio-Industries

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Biofortis

Nantes, Pays de la Loire Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IGNUT PEC10513

Identifier Type: -

Identifier Source: org_study_id